Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
February 12, 2019Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years Innate Pharma SA (...Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome
January 29, 2019Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) who have...Innate Pharma announces its financial calendar for 2019
January 10, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows: March 20, 2019: Publication of 2018 financial...Upcoming investor conferences
January 7, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events in the first quarter 2019: - LifeSci Advisors 1x1...Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
December 3, 2018Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...Innate Pharma announces publication of monalizumab research in the prestigious “Cell” journal widening the horizon of immune checkpoint inhibitors
November 30, 2018Monalizumab is a first-in-class broad-spectrum immune checkpoint inhibitor with a dual effect on both Natural Killer (NK) cells and T lymphocytes Monalizumab showed promising preclinical and clinical...
